Harvard Bioscience Inc (NASDAQ: HBIO) kicked off on Tuesday, down -3.78% from the previous trading day, before settling in for the closing price of $0.38. Over the past 52 weeks, HBIO has traded in a range of $0.37-$4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -3.49% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 50.00%. With a float of $38.01 million, this company’s outstanding shares have now reached $44.07 million.
In an organization with 355 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.35%, operating margin of -5.31%, and the pretax margin is -12.39%.
Harvard Bioscience Inc (HBIO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Harvard Bioscience Inc is 13.77%, while institutional ownership is 72.27%. The most recent insider transaction that took place on Jun 13 ’24, was worth 29,100. In this transaction Chief Executive Officer of this company bought 10,000 shares at a rate of $2.91, taking the stock ownership to the 3,111,091 shares. Before that another transaction happened on Jun 06 ’24, when Company’s Chief Executive Officer bought 20,000 for $3.07, making the entire transaction worth $61,400. This insider now owns 3,101,091 shares in total.
Harvard Bioscience Inc (HBIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 50.00% per share during the next fiscal year.
Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators
Take a look at Harvard Bioscience Inc’s (HBIO) current performance indicators. Last quarter, stock had a quick ratio of 0.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach 0.07 in one year’s time.
Technical Analysis of Harvard Bioscience Inc (HBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.4 million. That was better than the volume of 0.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 4.47%. Additionally, its Average True Range was 0.07.
During the past 100 days, Harvard Bioscience Inc’s (HBIO) raw stochastic average was set at 0.95%, which indicates a significant decrease from 5.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.13% in the past 14 days, which was higher than the 77.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9590, while its 200-day Moving Average is $2.1618. However, in the short run, Harvard Bioscience Inc’s stock first resistance to watch stands at $0.4433. Second resistance stands at $0.5167. The third major resistance level sits at $0.5633. If the price goes on to break the first support level at $0.3233, it is likely to go to the next support level at $0.2767. The third support level lies at $0.2033 if the price breaches the second support level.
Harvard Bioscience Inc (NASDAQ: HBIO) Key Stats
The company with the Market Capitalisation of 16.14 million has total of 44,074K Shares Outstanding. Its annual sales at the moment are 94,140 K in contrast with the sum of -12,410 K annual income. Company’s last quarter sales were recorded 24,560 K and last quarter income was 20 K.
